Analysts Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) PT at $103.62
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has earned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has earned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on […]
